Trial Profile
A randomized, double-blind, active-controlled study to assess the effect of LCZ696 compared with enalapril to improve exercise capacity in patients with heart failure with reduced ejection fraction (HFrEF)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms ACTIVITY-HF
- Sponsors Novartis; Novartis Pharmaceuticals
- 30 Sep 2021 Primary endpoint (Change From Baseline in Peak Respiratory Oxygen Uptake (VO2peak) Adjusted to Body Weight) After 3 Months of Treatment) has not been met as per results published in the European Journal of Heart Failure
- 30 Sep 2021 Results published in the European Journal of Heart Failure
- 09 Apr 2020 Status changed from active, no longer recruiting to completed.